Loading...

Rohit Bose, MD, PhD

Title(s)Assistant Professor, Anatomy
SchoolSchool of Medicine
Phone--
ORCID ORCID Icon0000-0002-6785-0697 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Toronto, CanadaMD/PhD2008Medicine & Molecular Genetics
    Weill Cornell Medicine, New YorkResidency, Medical Research Track2010Internal Medicine
    Memorial Sloan Kettering Cancer Center, New YorkFellowship, Medical Research Track2014Medical Oncology
    Memorial Sloan Kettering Cancer Center, New YorkFellowship2016Advanced Oncology
    Memorial Sloan Kettering Cancer Center, New YorkInstructor2018Dept. of Medicine, Genitourinary Service
    UCSF, San FranciscoAssistant ProfessorpresentDepts. of Anatomy, Medicine (Medical Oncology) & Urology
    UCSF Helen Diller Family Comprehensive Cancer Center, San FranciscoMemberpresentProstate Cancer Program
    UCSF Biomedical Sciences Graduate Program, San FranciscoFacultypresentCancer Biology & Human Genetics
    Collapse Awards and Honors
    Department of Defense, Prostate Cancer Program2016  - 2020Physician Research Training Award
    Prostate Cancer Foundation2016  - 2019Young Investigator Award
    Conquer Cancer Foundation / ASCO2016Merit Award
    Department of Defense, Prostate Cancer Program2013  - 2015Postdoctoral Research Training Award
    Conquer Cancer Foundation / ASCO2013  - 2014Young Investigator Award
    Dana Foundation, Memorial Sloan Kettering Cancer Center, Dana Foundation2011  - 2013Dana Fellow in Biomedical Research, Clinical Scholars Training Program
    Memorial Sloan Kettering Cancer Center2011John Mendelsohn Housestaff Teaching Award
    University of Toronto2008Lois & K.J.R. Wightman Award for Interest in Internal Medicine
    University of Toronto2007John Ruffo Graduate Fellowship for Outstanding Achievement during M.D./Ph.D.
    University of Toronto2007Dr. Ruth Kurdyak Memorial Medical Alumni Student Award
    University of Toronto2006Robert and Francine Ruggles Family Graduate Fellowship
    University of Toronto2005Medical Student Research Day Award
    University of Toronto2004Scholarship for ISREC Conference on Cancer Research
    Canadian Society for Clinical Investigation2004Young Investigator Award
    Canadian Institutes of Health Research2001M.D./Ph.D. Studentship
    Pfizer2000M.D./Ph.D. Studentship
    University of Toronto1999John McColl Memorial Award for high pre-medical standing
    McGill University1999(Declined) Jean Alloul Entrance Scholarship for M.D./Ph.D. Program
    Natural Sciences and Engineering Council Canada1999(Declined) Postgraduate Scholarship
    Society of Chemical Industry1999Merit in Biochemistry Award
    University of Saskatchewan1999J.F. Morgan Memorial Award for Highest Academic Achievement in Dept of Microbiology & Immunology
    University of Saskatchewan1999Biochemistry Scholarship for Highest Academic Achievement in Dept of Biochemistry
    University of Saskatchewan1999Earl of Bessborough Prize for Most Distinguished Graduate Receiving a B.Sc.
    University of Saskatchewan1999Haslam Medal for Most Distinguished Graduate of the College of Arts and Sciences
    University of Saskatchewan1995Entrance Scholarship for full tuition
    University of Toronto1995(Declined) Entrance Scholarship National Book Award

    Collapse Overview 
    Collapse Overview
    For more info, please visit rohitlab.org

    Our group's research falls into three overlapping themes:
    A. Hypermutation in Cancer
    B. Sensitization to Cancer Treatment
    C. Oncogene Networks

    A. Hypermutation in Cancer
    We study hypermutated subtypes of cancer via organoids, cell lines and murine systems. This enables us to investigate diverse aspects of cancer biology including: 1) our ability to model such patients' disease in vitro, ex vivo and in vivo, 2) to understand how oncogenic events functionally combine and cooperate to drive cancer formation and treatment resistance and 3) to experimentally define the determinants within the immune and tumor microenvironments that affect hypermutated tumor growth and response to therapy.

    B. Sensitization to Cancer Treatment
    Most pooled gene-knockout screens are powered to identify mediators of drug resistance. We are developing modified approaches that are powered instead to identify mediators and mechanisms of increased sensitivity to modern therapies. We have also completed whole-genome screens that suggest differing combinatorial treatment strategies depending on the tumor profile. One such set of results is leading us to investigate how epigenetic modifiers can be targeted in combination with standard-of-care therapies for a subset of prostate cancer patients.

    C. Oncogene Networks
    There are many protein families for which several members can individually give rise to cancer when dysregulated; for example, the ERG, ETV1 and ETV4 prostate oncogenes and the ERF prostate tumor suppressor (Bose et al, Nature, 2017), are some of the 30 members of the ETS transcription factor family. However, the frequency and mechanism of each alteration has a particular distribution for a given cancer, despite several family members being simultaneously expressed, with overlapping chromatin binding sites etc. Rather than studying individual mechanisms of gene, transcript and protein regulation, we are particularly interested in understanding how such families of cancer drivers compete, cooperate, become redundant and/or get bypassed, as well as determining whether processes occur within clones, or between clones. We also study related networks within normal cells, to understand how their dysregulation gives rise to tumor initiation.

    Collapse Research 
    Collapse Research Activities and Funding
    Investigating How a Balance of Negative and Positive ETS Factors Controls Prostate Oncogenesis
    NIH/NCI K08CA226348Sep 15, 2018 - Aug 31, 2023
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020 Jul 13. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. PMID: 32661416.
      View in: PubMed   Mentions:    Fields:    
    2. Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. Front Oncol. 2019; 9:1287. Ryan MJ, Bose R. PMID: 31824860.
      View in: PubMed   Mentions:
    3. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019 07; 571(7765):408-412. Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, Leslie CS, Sawyers CL. PMID: 31243370.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    4. Journal of Clinical Oncology. c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naïve prostate cancer that retains RB expression. 2018. View Publication.
    5. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature. 2017 06 29; 546(7660):671-675. Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV, Shah N, Sullivan PS, Doran MG, Wang P, Patruno A, Zhao Y, Zheng D, Schultz N, Sawyers CL. PMID: 28614298.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    6. A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. Proc Natl Acad Sci U S A. 2009 Aug 18; 106(33):14028-33. Viloria-Petit AM, David L, Jia JY, Erdemir T, Bane AL, Pinnaduwage D, Roncari L, Narimatsu M, Bose R, Moffat J, Wong JW, Kerbel RS, O'Malley FP, Andrulis IL, Wrana JL. PMID: 19667198.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansAnimalsCells
    7. Regulation of planar cell polarity by Smurf ubiquitin ligases. Cell. 2009 Apr 17; 137(2):295-307. Narimatsu M, Bose R, Pye M, Zhang L, Miller B, Ching P, Sakuma R, Luga V, Roncari L, Attisano L, Wrana JL. PMID: 19379695.
      View in: PubMed   Mentions: 141     Fields:    Translation:AnimalsCells
    8. Regulation of Par6 by extracellular signals. Curr Opin Cell Biol. 2006 Apr; 18(2):206-12. Bose R, Wrana JL. PMID: 16490351.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    9. Degradation of RhoA by Smurf1 ubiquitin ligase. Methods Enzymol. 2006; 406:437-47. Wang HR, Ogunjimi AA, Zhang Y, Ozdamar B, Bose R, Wrana JL. PMID: 16472676.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    10. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science. 2005 Mar 11; 307(5715):1603-9. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. PMID: 15761148.
      View in: PubMed   Mentions: 281     Fields:    Translation:HumansAnimalsCells
    11. High-throughput mapping of a dynamic signaling network in mammalian cells. Science. 2005 Mar 11; 307(5715):1621-5. Barrios-Rodiles M, Brown KR, Ozdamar B, Bose R, Liu Z, Donovan RS, Shinjo F, Liu Y, Dembowy J, Taylor IW, Luga V, Przulj N, Robinson M, Suzuki H, Hayashizaki Y, Jurisica I, Wrana JL. PMID: 15761153.
      View in: PubMed   Mentions: 247     Fields:    Translation:HumansAnimalsCells
    12. Income and spending patterns among panhandlers. CMAJ. 2002 Sep 03; 167(5):477-9. Bose R, Hwang SW. PMID: 12240813.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    13. Spectroscopic characterization by laser flash photolysis of electrophilic intermediates derived from 4-aminostilbenes. Stilbene "nitrenium" ions and quinone methide imines. Journal of the Chemical Society, Perkin Transactions 2. 1999; (8):1591 - 1600. Bose R, Ahmad A, Dicks A, Novak M, Kayser K, McClelland R.
    Rohit's Networks
    Concepts (93)
    Derived automatically from this person's publications.
    _
    Co-Authors (15)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _